E. David Crawford

19.1k total citations · 3 hit papers
161 papers, 6.8k citations indexed

About

E. David Crawford is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, E. David Crawford has authored 161 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 125 papers in Pulmonary and Respiratory Medicine, 43 papers in Oncology and 31 papers in Surgery. Recurrent topics in E. David Crawford's work include Prostate Cancer Treatment and Research (92 papers), Prostate Cancer Diagnosis and Treatment (85 papers) and Bladder and Urothelial Cancer Treatments (19 papers). E. David Crawford is often cited by papers focused on Prostate Cancer Treatment and Research (92 papers), Prostate Cancer Diagnosis and Treatment (85 papers) and Bladder and Urothelial Cancer Treatments (19 papers). E. David Crawford collaborates with scholars based in United States, Canada and France. E. David Crawford's co-authors include Catherine M. Tangen, Ian M. Thompson, M. Scott Lucia, George Wilding, Donald L. Trump, Judith Manola, Edward M. Messing, Michael Sarosdy, Phyllis J. Goodman and Charles A. Coltman and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

E. David Crawford

158 papers receiving 6.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter

2004 1.7k citations Catherine M. Tangen, E. David Crawford et al. New England Journal of Medicine profile →
Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate Cancer

1999 913 citations Edward M. Messing, Judith Manola et al. New England Journal of Medicine profile →
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial

2023 99 citations E. David Crawford, Neal D. Shore et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by E. David Crawford

Since Specialization

Citations

This map shows the geographic impact of E. David Crawford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. David Crawford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. David Crawford more than expected).

Fields of papers citing papers by E. David Crawford

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. David Crawford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. David Crawford. The network helps show where E. David Crawford may publish in the future.

Co-authorship network of co-authors of E. David Crawford

This figure shows the co-authorship network connecting the top 25 collaborators of E. David Crawford. A scholar is included among the top collaborators of E. David Crawford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. David Crawford. E. David Crawford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical Considerations after a Negative Prostate Biopsy 2016 ·E. David Crawford, Neal D. Shore, Matthew R. Cooperberg, Marc Dall’Era, Francisco G. La Rosa	3
2	Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care System 2016 ·World Journal of Urology ·S. Scott Sutton, E. David Crawford, Judd W. Moul, James W. Hardin, (unknown)	4
3	Measurement of testosterone: how important is a morning blood draw? 2015 ·Current Medical Research and Opinion ·E. David Crawford, Wendy Poage, Allen W. Nyhuis, David A. Price, Sherie A. Dowsett, (unknown), David Muram	14
4	The Accuracy of Prostate Cancer Localization Diagnosed on Transrectal Ultrasound-Guided Biopsy Compared to 3-Dimensional Transperineal Approach 2013 ·Advances in Urology ·(unknown), (unknown), Jason M. Phillips, (unknown), Daniel R. Smith, Colin O’Donnell, E. David Crawford, Al B. Barqawi	8
5	Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer 2013 ·Current Opinion in Urology ·Kyle O. Rove, E. David Crawford	6
6	Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts 2011 ·World Journal of Urology ·Kyle O. Rove, E. David Crawford	2
7	Comorbidity and Mortality Results From a Randomized Prostate Cancer Screening Trial 2010 ·Journal of Clinical Oncology ·E. David Crawford, Robert L. Grubb, Amanda Black, Gerald L. Andriole, Ming‐Hui Chen, Grant Izmirlian, Christine D. Berg, Anthony V. D’Amico	98
8	Endogenous sex hormones and the risk of prostate cancer: A prospective study 2008 ·International Journal of Cancer ·Jocelyn M. Weiss, Wen‐Yi Huang, Sabina Rinaldi, Thomas R. Fears, Nilanjan Chatterjee, Ann W. Hsing, E. David Crawford, Gerald L. Andriole, Rudolf Kaaks, Richard B. Hayes	47
9	Repeat prostate biopsy in the Prostate, Lung, Colorectal and Ovarian cancer screening trial 2007 ·British Journal of Urology ·Paul F. Pinsky, E. David Crawford, Barnett S. Kramer, Gerald L. Andriole, Edward P. Gelmann, Robert L. Grubb, Robert T. Greenlee, John K. Gohagan	29
10	Validation of citrate and derivatives in expressed prostatic secretions to predict prostate cancer: High-resolution 1H-NMR study 2006 ·Cancer Research ·Natalie J. Serkova, Eduard J. Gamito, Richard H. Jones, Colin O’Donnell, E. David Crawford	2
11	Southwest oncology group phase II study of arsenic trioxide in patients with refractory germ cell malignancies 2006 ·Cancer ·Tomasz M. Beer, Catherine M. Tangen, Craig R. Nichols, Kim Margolin, Robert Dreicer, William Stephenson, David I. Quinn, Derek Raghavan, E. David Crawford	23
12	Correlation between LUTS (AUA-SS) and erectile dysfunction (SHIM) in an age-matched racially diverse male population: data from the Prostate Cancer Awareness Week (PCAW) 2005 ·International Journal of Impotence Research ·Al B. Barqawi, (unknown), Rajiv Kumar, Hari K. Koul, E. David Crawford	22
13	Herbal and vitamin supplement use in a prostate cancer screening population 2004 ·Urology ·Albaha Barqawi, Eduard J. Gamito, Colin O’Donnell, E. David Crawford	10
14	Impact of different variables on the outcome of patients with clinically confined prostate carcinoma 2001 ·Cancer ·Ali Ziada, (unknown), Peter B. Snow, Richard F. Levine, Gary J. Miller, E. David Crawford	26
15	Comparison of telomerase activity and GSTP1 promoter methylation in ejaculate as potential screening tests for prostate cancer 2000 ·Molecular and Cellular Probes ·(unknown), Tait D. Shanafelt, (unknown), Kenneth R. Shroyer, (unknown), E. David Crawford, Gary J. Miller, (unknown), L. Michael Glodé	50
16	Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate Cancer breakdown → 1999 ·New England Journal of Medicine ·Edward M. Messing, Judith Manola, Michael Sarosdy, George Wilding, E. David Crawford, Donald L. Trump	913
17	Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial 1998 ·Urology ·G.L. Andriole, H. A. Guess, Jonathan I. Epstein, Henry Wise, Dov Kadmon, E. David Crawford, Perry B. Hudson, (unknown), Nicholas A. Romas, Lynn Patterson, Thomas J. Cook, Joanne Waldstreicher	138
18	The effect of ejaculation on prostate-specific antigen in a prostate cancer-screening population 1998 ·Urology ·(unknown), (unknown), (unknown), E. David Crawford	21
19	Phase II evaluation of piroxantrone in renal cell carcinoma 1992 ·Investigational New Drugs ·Ace Allen, Michael Wolf, E. David Crawford, Mellar P. Davis, Ronald B. Natale, (unknown)	6
20	Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study 1992 ·European Journal of Cancer ·C. Kent Osborne, Geoffrey R. Weiss, Brent A. Blumenstein, E. David Crawford, Ronald M. Bukowski, (unknown)	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact